Lupo KB - Search Results

1

Engineered NKG2C ⁺ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome.

Lupo KB, Panjwani MK, Shahid S, Sottile R, Lawry C, Kolk G, Kontopolous T, Daniyan AF, Chandran SS, Klebanoff CA, Hsu KC. Lupo KB, et al. bioRxiv [Preprint]. 2024 Aug 1:2024.07.16.603785. doi: 10.1101/2024.07.16.603785. bioRxiv. 2024. PMID: 39211122 Free PMC article. Preprint.

2

synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.

Lupo KB, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, McIntosh M, Matosevic S. Lupo KB, et al. Nat Commun. 2024 Mar 1;15(1):1909. doi: 10.1038/s41467-024-46343-3. Nat Commun. 2024. PMID: 38429294 Free PMC article.

3

TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma.

Lupo KB, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Cohen-Gadol AA, Slivova V, McIntosh M, Pollok KE, Matosevic S. Lupo KB, et al. iScience. 2023 Oct 28;26(12):108353. doi: 10.1016/j.isci.2023.108353. eCollection 2023 Dec 15. iScience. 2023. PMID: 38053639 Free PMC article.

4

Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.

Chambers AM, Lupo KB, Wang J, Cao J, Utturkar S, Lanman N, Bernal-Crespo V, Jalal S, Pine SR, Torregrosa-Allen S, Elzey BD, Matosevic S. Chambers AM, et al. Among authors: lupo kb. Elife. 2022 Jul 11;11:e73699. doi: 10.7554/eLife.73699. Elife. 2022. PMID: 35815945 Free PMC article.

5

Functional expression of CD73 on human natural killer cells.

Chambers AM, Wang J, Dao TN, Lupo KB, Veenhuis P, Ayers MG, Slivova V, Cohen-Gadol AA, Matosevic S. Chambers AM, et al. Among authors: lupo kb. Cancer Immunol Immunother. 2022 Dec;71(12):3043-3056. doi: 10.1007/s00262-022-03219-z. Epub 2022 May 25. Cancer Immunol Immunother. 2022. PMID: 35622118 Free PMC article.

6

Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.

Lupo KB, Moon JI, Chambers AM, Matosevic S. Lupo KB, et al. Cytotherapy. 2021 Oct;23(10):939-952. doi: 10.1016/j.jcyt.2021.05.001. Epub 2021 Jul 14. Cytotherapy. 2021. PMID: 34272175

7

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.

Lupo KB, Matosevic S. Lupo KB, et al. J Hematol Oncol. 2020 Jun 12;13(1):76. doi: 10.1186/s13045-020-00913-2. J Hematol Oncol. 2020. PMID: 32532329 Free PMC article. Review.

8

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.

Lupo KB, Matosevic S. Lupo KB, et al. Cancers (Basel). 2019 Jun 3;11(6):769. doi: 10.3390/cancers11060769. Cancers (Basel). 2019. PMID: 31163679 Free PMC article. Review.

9

Purinergic targeting enhances immunotherapy of CD73⁺ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells.

Wang J, Lupo KB, Chambers AM, Matosevic S. Wang J, et al. Among authors: lupo kb. J Immunother Cancer. 2018 Dec 4;6(1):136. doi: 10.1186/s40425-018-0441-8. J Immunother Cancer. 2018. PMID: 30514403 Free PMC article.

10

Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells.

Chambers AM, Lupo KB, Matosevic S. Chambers AM, et al. Among authors: lupo kb. Front Immunol. 2018 Nov 8;9:2517. doi: 10.3389/fimmu.2018.02517. eCollection 2018. Front Immunol. 2018. PMID: 30467503 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters